SAN CARLOS, Calif., Dec 14, 2006 (BUSINESS WIRE) -- Nektar Therapeutics (Nasdaq:NKTR) reported that Pfizer Inc said today that the U.S. District Court for the Southern District of New York has denied a motion for a preliminary injunction that would have blocked further sales of its inhalable insulin medication, Exubera(R), in the U.S. The preliminary injunction was requested by Novo Nordisk as part of a patent infringement case that will be heard by the same court.
Exubera, a product of a developmental collaboration between Pfizer and Nektar, is the only inhalable form of insulin to be approved by the Food and Drug Administration (FDA). The court's decision allows the product to remain on the U.S. market, and available to patients, while the case proceeds to trial.
SOURCE: Nektar Therapeutics
Nektar Therapeutics Joyce Strand, 650-631-3138 Jennifer Ruddock, 650-631-4954
Copyright Business Wire 2006
News Provided by COMTEX